Solzia Pharmaceuticals

Solasia Pharma is a specialty pharmaceutical company based in Japan that focuses on the development and commercialization of innovative oncology medicines and supportive care products. The company targets unmet medical needs in the Asian market, particularly in Japan and China, by in-licensing promising drug candidates from Western biotech and pharmaceutical firms. Its commercial portfolio includes Sancuso for chemotherapy-induced nausea and vomiting, Episil for oral mucositis, and Darvias for peripheral T-cell lymphoma. Solasia operates with a lean business model, leveraging strategic partnerships for manufacturing and large-scale distribution while maintaining internal expertise in clinical development and regulatory affairs.